Metabolomics in preclinical and clinical research

Pharma
Pharma

Metabolomics in preclinical and clinical research

Pharmacometabolomics

Lack of translatability from preclinical to clinical stages, toxicities and non-response remain prevalent in drug development, leading to high attrition rates across indications. Metabolomics has proven to be a versatile tool across the pharmaceutical R&D cycle, improving the understanding of how new therapeutic agents act, ultimately providing insights for personalized therapies.

Metabolomics increases success rates at all stages of pharmaceutical development

Only around one in 5,000 compounds tested in the discovery stage are approved for routine use.
Even then, further limitations arise in real-world settings

  • Non-response is common, with more than 1 in 3 patients experiencing no clinical benefit
  • Drugs may become ineffective due to acquired resistance mechanisms and/or progression of disease
  • There is a lack of actionable biomarkers to determine the best course of therapy

With metabolomics, researchers can increase their knowledge of compound biology, so they can identify drug actions beyond the immediate target and improve prioritization of promising compounds.

Metabolic profiling more accurately replicates pathophysiology, facilitating translation of preclinical findings into clinical research.

And with comprehensive patient phenotyping based on an understanding of biomarker response and genetic and environmental factors, it’s possible to identify the right course of therapy to improve outcomes and mitigate risks.

See metabolomics in action across the research cycle

A quantitative metabolomics biomarker strategy increases the success probability of your compound

Discovery

  • Mode of action
  • Compound prioritization

Preclinical
research

  • Response biomarker
  • Dosage | mode of delivery
  • Molecular toxicology

Clinical
development

  • Dose verification
  • Safety biomarker
  • Resistance or relapse

Approval |
Market

  • Patient stratification
  • Prediction of response
  • Performance CDx

Discovery

Preclinical
research

Clinical
development

Approval |
Market

Functional-Microbiomics_Mikroben

In vitro studies | Cell lines

  • Leverage the fact that metabolism is highly conserved across species
  • Replicate findings from previous academic research with standardized quantification
Functional-Microbiomics_Mikroben

Ease your choice

  • Test more parameters to prioritize the most useful
  • Understand relevant metabolic pathways using thousands of metabolites and over 400 metabolism indicators

Case study
Advancing cancer treatment by targeting dysregulated metabolism – A roadmap

In this webinar, Dr. Anna Halama (from Weill Cornell Medicine, Qatar) gives an overview of the application of metabolomics in the mechanistic study of cancer in cell cultures and xenografts.

Open in YouTube

YouTube

By loading the video, you agree to YouTube's privacy policy.
Learn more

Load video

Discovery

Preclinical
research

Clinical
development

Approval |
Market

Functional-Microbiomics_Mikroben

Translate insights from "mouse to man"

  • Toxicological parameters are reflected in metabolic alterations
  • Mode of action is reflected in metabolic alterations
  • Metabolism is highly conserved across species
Expand-Data-Readout_Lupe-Phiolen

Improve translation with preferred technology

  • Metabolomics is highly sensitive
  • Low sample volume allows sequential sampling to reduce animal demand
  • Understand relevant metabolic pathways using over 400 metabolism indicators

Case study – PI3K inhibition metabolomic biomarkers

22 of 26 dose-dependent metabolic mouse biomarkers successfully translate into clinical research phase I
(ICR London)

Read the full paper by Ang et al., 2016
Request more case studies – Preclinical and translational research
Talk to an expert

Signaling pathways, targets and metabolites

Metabolic effects of different cancer drugs in the same signalling network.
(adapted from work by Florence Raynaud)

Discovery

Preclinical
research

Clinical
development

Approval |
Market

Increase clinical potential

  • Identify likely responders
  • Get actionable insights for patient care and therapy optimization
  • Keep patient safety in check over the whole trial period
Functional-Microbiomics_Mikroben

Scalable and reproducible solution

  • Short turn-around times
  • Closely observe patients through scalable turn-around times
  • Measure safety- and response biomarkers in different laboratories around the world

Commentary – Adverse effects in immunotherapy

There is growing evidence that metabolomics can provide useful biomarkers for patient outcomes in immunotherapy. Stefan Ledinger, Director of Business Development at biocrates, summarizes views on the role of metabolism in regulating immune responses and perturbations in immunometabolic pathways.

Woman Immunotherapy

Why do we need to understand the role of metabolism in immunotherapy?

Discovery

Preclinical
research

Clinical
development

Approval |
Market

Optimize treatment

  • Tailor treatment to patients’ individual biochemical response
  • Improve treatment outcomes and achieve higher patient satisfaction
  • Deliver results from precision medicine to precision health
Functional-Microbiomics_Mikroben

Implement and scale with ease

  • Laboratory onboarding takes less than a week
  • Fully quality-controlled kit solution
  • Globally certified partner network to scale throughput to match demand

Case study
Metabolomics leading the way from stratification to precision medicine

Metabolomics was used to understand immunotherapy response in urological cancers, revealing unconventional supplementation options to make drug treatment more effective.

Cancer-cells

Make sure your drug fits to your cancer

More resources

Find out more in our pharma brochure
The key to personalized therapies – how to cross the translation barrier with metabolomics in pharmaceutical R&D

Related phenotyping products

MxP® Quant 500 XL

The largest combination of lipids and small molecules for quantitative metabolic profiling in a single kit

AbsoluteIDQ® p400 HR

The high performance, high resolution tool for targeted metabolomics profiling

Tryptophan metabolism assay

Metabolomics at the intersection of immunity, neuronal function, and
gut homeostasis

Talk to an expert

biocrates life sciences ag
Eduard-Bodem Gasse 8
6020 Innsbruck | AUSTRIA
Phone +43 512 579823
Fax +43 512 579823-329

biocrates inc.
26895 Aliso Creek Rd Ste B-426
Aliso Viejo, CA 92656-5301
Phone +1 774 424 8150
Operating hours: Mo – Fr | 9 am – 7 pm (EST)

For research use only | not for use in diagnostic procedures.

Newsletter      Literature      Imprint      Terms & Conditions      Privacy Policy

2023 © biocrates life sciences ag